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Psychosis and/or aggression are common problems in dementia, and when severe or 
persistent, cause considerable patient distress and disability, caregiver stress, and early 
institutionalization. In 2005, the Food and Drug Administration (FDA) determined that 
atypical antipsychotics were associated with a significantly greater mortality risk compared 
to placebo, which prompted the addition of an FDA black-box warning. The American 
College of Neuropsychopharmacology (ACNP) White Paper, 2008, reviewed this issue 
and made clinical and research recommendations regarding the use of antipsychotics 
in dementia patients with psychosis and/or agitation. Increased mortality risk has also 
been described in cerebrovascular adverse events in elderly users of antipsychotics. In 
the present work, at the translational level, we used male 3xTg-AD mice (PS1M146V, 
APPSwe, tauP301L) at advanced stages of the disease reported to have worse survival 
than females, to study the behavioral effects of a low chronic dose of risperidone (0.1 mg/
kg, s.c., 90 days, from 13 to 16 months of age) and its impact on long-term survival, as 
compared to mice with normal aging. Animals were behaviorally assessed for cognitive 
and BPSD (behavioral and psychological symptoms of dementia)-like symptoms in 
naturalistic and experimental conditions (open-field test, T-maze, social interaction, Morris 
water maze, and marble test) before and after treatment. Weight, basal glucose levels, 
and IPGTT (i.p. glucose tolerance test) were also recorded. Neophobia in the corner 
test was used for behavioral monitoring. Survival curves were recorded throughout the 
experiment until natural death. The benefits of risperidone were limited, both at cognitive 
and BPSD-like level, and mostly restricted to burying, agitation/vibrating tail, and other 
social behaviors. However, the work warns about a clear early mortality risk window 
during the treatment and long-lasting impact on survival. Reduced life expectancy and 
life span were observed in the 3xTg-AD mice, but total lifespan (36 months) recorded in 
C57BL/6 × 129Sv counterparts with normal aging was also truncated to 28 months in 
those with treatment. Sarcopenia at time of death was found in all groups, but was more 
severe in wild-type animals treated with risperidone. Therefore, the 3xTg-AD mice and 
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INTRODUCTION
Behavioral changes and neuropsychiatric symptoms (NPS), also 
known as ’’behavioral and psychological symptoms of dementia 
(BPSD),” may occasionally signal the onset of Alzheimer’s disease 
(AD) (Reisberg et al., 1987). They are present in 90% of patients as 
the disease progresses in a neurodegenerative process which is faster 
and more severe in males in spite of similar incidence of AD among 
sexes or women showing higher incidence with increasing age 
(Lapane et al., 2001; Pike, 2017; Rezanni et al., 2019). The prevalence 
of delusions in patients with AD is between 9% and 63% and that 
of hallucinations is between 4% and 41%; the rate of aggression is 
between 11% and 46% and agitation has an even higher prevalence 
rate among 20–80% (Jeste et al., 2008). Most of these symptoms 
diminish the quality of life of the patients and, particularly, the 
psychosis is associated with a rapid cognitive deterioration (reviewed 
by Cummings, 2000 and Kalman et al., 2008). The cognitive decline 
characteristic of dementia is also associated with an increase in social 
vulnerability in humans that sometimes leads to death (Andrew and 
Rockwood, 2010). Therefore, these neuropsychiatric symptoms 
present diverse clinical implications in patients, as is the specific case 
of psychosis, agitation, and aggression, which increase the burden of 
disease, also resulting a strong cause of distress among the familiar 
and professional caregivers (Tan et al., 2005).
During the last two decades, the most recent atypical 
antipsychotic drugs that have been approved by the Food and 
Drug Administration of the US Department of Health and Human 
Services (US FDA) are risperidone in 1993, olanzapine in 1996, 
quetiapine in 1997, ziprasidone in 2001, and aripiprazole in 2002. 
These atypical antipsychotics have replaced the first-generation 
antipsychotics such as haloperidol and thioridazine (Schneider et 
al., 2005 and Jeste et al., 2008). Atypical antipsychotics are used 
as the first line of pharmacological approach for the treatment 
of neuropsychiatric symptoms in AD (Ballard et  al., 2009). In 
the present work, we focused on risperidone, one of the most 
used atypical antipsychotics and co-administered with different 
types of drugs. At the pharmacological level, risperidone is a 
selective monoaminergic antagonist, which has a high affinity 
with serotonergic receptors 5-HT2 and dopaminergic D2 and 
binds also to α1 adrenergic receptors and with lower affinity 
to histaminergic H1 and α2 adrenergic receptors. It has been 
approved by the FDA for the treatment of schizophrenia (positive 
and negative symptoms), bipolar disorders, and autism. It is also 
used in dementia, depression, obsessive-compulsive disorders, 
personality disorders, and attention deficit hyperactivity disorder 
(Katz et al., 2007; Shekelle et al., 2007 and Rodriguez-Antona 
et  al., 2009). This drug has a moderate but significant effect on 
short-term treatment (> 6–12 weeks) for aggression but is limited 
in long-term therapy, whereas for agitation symptoms, the 
results are not well established. In addition, there’s an increase 
in the concerns about adverse outcomes with these treatments, 
including strokes and death (Ballard et al., 2009).
In April 2005, the FDA issued the following warning for all 
atypical antipsychotics based on their evaluations: “The FDA 
informed health professionals and the public about the increased 
risk of mortality in elderly patients who received atypical 
antipsychotic drugs for the treatment of dementia-related 
psychosis. Analyses of 17 placebo-controlled trials involving 5,377 
elderly patients with conduct disorders associated with dementia 
revealed a risk of death in patients treated with the drug between 
1.6 and 1.7 times that observed in patients treated with placebo. 
The mortality rate in the drug-treated patients was approximately 
4.5% compared to a rate of approximately 2.6% in the placebo 
group. Although the causes of death were varied, most of the deaths 
appeared to be cardiovascular (for example, heart failure, sudden 
death) or infectious (pneumonia)”. Based on this analysis, the FDA 
requested manufacturers of the atypical antipsychotic drugs to 
include information about this risk in the package leaflet of the 
drug (Jeste et al., 2008). These alerts brought a diversity of opinions 
in the scientific community. Some authors considered the warnings 
about atypical antipsychotics as alarming and potentially harmful 
for patients with dementia, while others were concerned that there 
was no clear evidence to support a greater benefit in relation to 
atypical antipsychotics compared to conventional antipsychotics 
(Trifiro et al., 2009). In a previous work at our UVaMiD neurology 
unit, we studied the mortality risk in AD patients at advanced ages 
of the disease who received risperidone therapy, but we could not 
find any relationship to metabolic syndrome nor history of heart 
disease (Vilalta-Franch et al., 2008).
This diversity of opinions can be observed in studies of 
circadian cycle disorders where patients with dementia after 
a 12-week treatment at a dose of 1.49 mg/day of risperidone 
reported improvements in total sleep hours, waking hours in bed, 
insomnia, and other variables related to sleep (Durán et al., 2005). 
Other studies have indicated that in elderly patients with dementia 
low doses of risperidone 0.5 and 1 mg were well tolerated and 
were associated with reductions in BPSD, in particular, agitation, 
aggression, irritability, delusions, sleep disturbances, anxiety, 
and phobias. Despite efficacy in the reduction of various adverse 
symptoms, risperidone and olanzapine should not be used 
routinely for the treatment of aggression and psychosis in patients 
with dementia (Onor et al., 2007). Other studies have indicated 
that risperidone and olanzapine increase the risk of mortality in 
elderly patients with dementia with an increased risk of the latter 
over the former (Vilalta-Franch et al., 2008). Also, mortality risks 
are increased with high doses of atypical antipsychotics and the 
their non-transgenic counterparts can be useful to delimitate critical time windows and 
for studying the physio-pathogenic factors and underlying causal events involved in this 
topic of considerable public health significance.
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causes of mortality are cerebrovascular accidents, respiratory 
diseases, and circulatory disorders (Huybrechts et al., 2012) 
compared with people who received placebo (Trifiro et al., 2009). 
Cerebrovascular risks (CVA) are especially observed during 
the first weeks of treatment; this risk decreases with time and 
normalizes after 3 months of treatment (Kleijer et al., 2009). 
Currently, atypical antipsychotics continue to be used under strict 
supervision and monitoring in some hospitals and/or geriatrics 
for the BPSD. This is even though older people are more sensitive 
to their side effects than young and middle-aged adults, in part 
by the interaction of changes caused by age and pharmacological 
sensitivity to antipsychotic treatments (Salzman et al., 2008).
Due to the variety of results and the ethical impossibility of 
conducting new clinical studies in humans, it is important to 
model the pharmacological responses of antipsychotics in animal 
models of the disease and to study their effects in the BPSD. At 
the translational level, the triple transgenic mouse for AD hosts 
human transgenes PS1/M146V, APPswe, and tau P301L (Oddo 
et al., 2003a). These rodents uniquely mimic various symptoms 
of the disease in a temporal and neuroanatomical pattern similar 
to that observed in humans (Belfiore et al., 2019). The onset of 
symptoms has been established between 4 and 6 months of age 
and involves electrophysiological deficits (in LTP, long term 
potentiation and fEPSP, field excitatory postsynaptic potential) 
at the hippocampal level, learning and memory problems, 
cholinergic deficiencies, and emotional disturbances. However, 
at these ages, the brains of the animals only show presence of 
intraneuronal immunoreactivity of Aβ (Kitazawa et al., 2005; 
Giménez-Llort et al., 2007; Oddo et al., 2003a; Oddo et al., 2003b). 
After 12 months of age, the neuropathological profile finds its 
parallelism with the advanced stages of the disease in humans, 
with the characteristic deposits of Aβ and neurofibrillary tangles 
of tau protein (Oddo et al., 2003a; Oddo et al., 2003b). We have 
previously shown increased mortality in male 3xTg-AD mice as 
compared to females, ranging from 33% (Giménez-Llort et al., 
2008) to 100% at 15 months of age (García-Mesa et al., 2012) 
and its relation to impaired neuroimmunoendocrine system 
(Giménez-Llort et al., 2014). The increased impact of AD (faster, 
more severe) of male sex has recently also been reported in the 
human patient (Pike, 2017; Rezanni et al., 2019).
The present study aims to model in 3xTg-AD mice the 
vulnerability that leads to an increase in mortality observed in 
patients with AD chronically treated with atypical antipsychotics 
such as risperidone. Before we can address this modeling, we 
defined the starting phenotype of the subject of study. To this 
end, the animals were evaluated in a battery of tests for measuring 
exploratory activity, anxiety, learning and memory, burying of 
objects, and social behavior. An assessment of the basal state 
of glucose and the tolerance response to it when administered 
intraperitoneally was also made.
MATERIALS AND METHODS
Animals
Homozygous triple-transgenic 3xTg-AD mice harboring human 
PS1/M146V, APPSwe, and tauP301L transgenes were genetically 
engineered at the University of California Irvine, as previously 
described (Oddo et al., 2003b). Briefly, two independent 
transgenes (encoding human APPSwe and human tauP301L, 
both under control of the mouse Thy1.2 regulatory element) were 
co-injected into single-cell embryos harvested from homozygous 
mutant PS1M146V knock-in (PS1KI) mice. The PS1 knock-in 
mice were originally generated as a hybrid C57BL/6 x 129Sv.
Forty-six 12-month-old 3xTg-AD mice (n = 23) and 
C57BL/6 x 129Sv (n = 23) wildtype mice (from now, referred as 
non-transgenic mice, NTg) from litters of a breeding program 
established in our laboratory at the Medical Psychology Unit, 
Universitat Autònoma de Barcelona, were used in this study. All 
the animals were housed three to four per cage and maintained 
(Makrolon, 35 × 35 × 25 cm) under standard laboratory 
conditions (12 h light/dark, cycle starting at 8:00h, food and 
water available ad libitum, 22 ± 2ºC, 50–60% humidity). The 
circadian activity was recorded during one whole light/dark (LD) 
period, and the rest of the tests from 9:00h to 13:00h.
This study was carried out in accordance with the 
recommendations of ARRIVE guidelines developed by the NC3Rs 
(Kilkenny et al., 2010) and the Spanish legislation on “Protection 
of Animals Used for Experimental and Other Scientific Purposes” 
and the European Communities Council Directive (2010/63/
EU) on this subject. The protocol CEEAH 2481/DMAH 8700 
entitled “Risk factors and preventive/therapeutical strategies in 
Alzheimer’s disease: studies in triple-transgenic 3xTg-AD mice” 
was approved by Departament de Medi Ambient i Habitatge, 
Generalitat de Catalunya.
Experimental Design and Risperidone 
Treatment
A longitudinal study divided into successive phases including 
a “before–after treatment” design was performed. The study 
started at 12 months of age; that in the 3xTg-AD mice has been 
extensively reported mimicking neuropathological hallmarks 
of the disease (Belfiore et al., 2019) and that in the NTg mice 
(C57BL/6 x 129Sv genetic background) corresponds to middle 
age. The sample of NTg mice was segregated into two groups 
according to the activity levels exhibited in the corner test 
(CT) for neophobia and the open-field (OF) test, to be used 
as controls that will be treated with saline (NTg mice with low 
motor activity) or risperidone (NTg mice with high motor 
activity), respectively.
Risperidone was used at a dose of 0.1 mg/kg equivalent 
to that administered in patients with AD and used in most 
experimental work performed in rodents (Bruins Slot et al., 
2005). The chronic administration, subcutaneous for 3 months 
from 13 to 16 months of age, rotated three injection sites (the 
neck and the two flanks).
First, we characterized the basal phenotype (phase 1, weeks 
1–6, phenotype “before treatment”; animals at 12 months of 
age). As in the case of geriatric patients, the treatment regimen 
was initiated with a lower dose of 0.05 mg/kg (phase 2, low dose 
and follow-up tests, week 7; animals at 13 months of age). After 
7 days, the final dose of 0.1 mg/kg was started and behavioral 
effects assessed (phase 3, treatment and behavioral effects 
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“after treatment”, weeks 8–16; animals until 15 months of age). 
Thereafter, treatment followed without behavior and completed 
the total period of 3 months of subcutaneous treatment (phase 4, 
only treatment, until 16 months of age). From that moment and 
until the end of their days, the variables of weight and survival 
were recorded continuously with a weekly or daily cadence, 
respectively (phase 5, from 16 to 36 months of age).
Four experimental groups were studied and are plotted in the 
before/after graphs of the figures as follows: NTg mice (s) (NTg 
mice that will receive or have received saline, n = 12), NTg mice 
(r) (NTg mice that will receive or have received risperidone, n = 
11), 3xTg-AD mice (s) (3xTg-AD mice that will receive or have 
received saline, n = 12), and 3xTg-AD (r) (3xTg-AD mice that 
will receive or have received risperidone, n = 11).
Behavioral Assessments
Behavioral assessment consisted in a battery of naturalistic 
and experimental conditions (Giménez-Llort et al., 2007). 
Neophobia in the CT was used for behavioral monitoring 
through the treatment.
Corner Test (CT)
Animals were individually placed in the center of a clean standard 
home cage, filled with wood shave bedding. Number of corners 
visited were recorded during 30 s (Belzung and Le Pape, 1994). 
Latency to realize the first rearing, and the number of rearings 
were also registered (Giménez-Llort et al., 2007).
Open Field Test (OF)
Immediately after the CT, mice were placed in the center of an 
open field (homemade woodwork, white box, 50 × 50 × 20 cm) 
and observed for 5 min (Hall and Ballachey, 1932). The 
ethogram, described by the temporal profile of the following 
sequence of behavioral events, was recorded: duration of freezing 
behavior, latency to leave the central square and that of entering 
the peripheral ring, as well as latency and total duration of self-
grooming behavior. Horizontal (crossings of 10 × 10 cm squares) 
and vertical (rearings with a wall support) locomotor activities 
were also measured. Bizarre behaviors observed in this test were 
also measured according to the previous reported criterion 
(Baeta-Corral and Giménez-Llort, 2014). During the tests, 
defecation boli and urination were also recorded as measures of 
individual differences in emotionality (Hall, 1934).
T-Maze (TM)
Working memory was assessed by means of a spontaneous 
alternation task (Douglas, 1966) in a black TM. The apparatus 
consisted of a woodwork, three arms of 30 × 5 × 20 cm connected 
by a 5 × 5 × 20 cm intersection. The animal was placed inside 
the “vertical” arm of the maze with its head facing the end wall, 
and it was allowed to explore the maze during a maximum of 3 
min. Freezing behavior (latency to move), the latency to reach 
the intersection, the total time invested to explore the three arms 
of the maze, and the number of errors (revisiting an arm) were 
recorded. Defecation boli and urination were also noted.
Social Interaction Test (SIT)
Behavioral signatures of social dysfunction in 3xTg-AD mice 
were assessed by means of the SIT (File and Hyde, 1978) as 
recently described (Torres-Lista and Giménez-Llort, 2019). A 
dyad of two unfamiliar mice of the same genotype and sex were 
introduced in a standard home cage and video recorded for 5 
min. Behaviors were classified into social (social investigation, 
aggression, vibrant tail) and non-social (exploring, digging, 
self-grooming) interactions. We also scored the total number of 
episodes and their total duration.
Morris Water Maze (MWM)
A 5-day place learning task for short- and long-term spatial 
reference memory (four trial sessions per day, with trials spaced 
30 min apart) was followed 2 h 30 min later by a probe trial 
(removal of the platform) for short-term memory in the MWM 
(Morris, 1981; Morris, 1984). Mice were trained to locate a 
hidden platform (7-cm diameter, 1 cm below the water surface) 
in a circular pool for mice (Intex Recreation Corp., Long Beach, 
CA, United States; 91-cm diameter, 40-cm height, 25°C opaque 
water), located in a completely black painted 6-m2 test room. 
Mice that failed to find the platform within 60 s were placed 
on it for 10 s, the same period as was allowed for the successful 
animals. White geometric figures, one hung on each wall of the 
room, were used as external visual clues. Behavior was evaluated 
by direct observation and analysis of videotape-recorded images. 
Variables of time (escape latency) and quadrant preference and 
entries were analyzed in all the trials of the tasks. The escape 
latency was readily measured with a stopwatch by an observer 
unaware of the animal’s genotype and confirmed during the 
subsequent video-tracking analysis. In the probe trial, the time 
spent and number of entries in each of the four quadrants were 
also measured retrospectively by means of the automated video-
tracking analysis.
Marble Burying Test (MB)
The procedure for MB was adopted with minor modifications 
from that originally described by Broekkamp et al. (1986). 
Mice were placed individually in a standard home cage 
containing six glass marbles (1 × 1 × 1 cm) evenly spaced 
making a triangle (three rows of three, two, and one marble 
per row only in the left area of the cage) on a 5-cm-thick 
layer of sawdust. The mice were left in the cage with marbles 
for a 30-min period after which the test was terminated by 
removing the mice and counting the number of marbles: intact 
(untouched), rotated or at least half buried by sawdust, and 
buried (completely  hidden) as previously described (Torres-
Lista et al., 2015)
Body Weight (BW) and Basal Glucose 
Levels (G)
Throughout the experimental process, evaluation of weight and 
survival was continuously monitored until the natural end of 
the life of the animals. The blood samples were taken from an 
incision made at the tip of the tail.
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Survival Curve
The survival curves were obtained with the percentage of animals 
that were maintained throughout the experimental procedure.
Statistics
Statistical analysis were performed using SPSS 17.0 software. 
The results are expressed as means ± SEM or percentage. A 2×2 
factorial design with multivariate general lineal model analysis 
evaluated genotype (G) and treatment (T) effects, followed by 
post hoc Tukey B test. In the Morris water maze, the factor ‘day 
(D)’ was included when appropiate. Student’s t-test was used to 
compare two independent groups. The comparisons for related 
samples were made with the paired t-test. Survival curve was 
analyzed with Kaplan-Meier test. The correlations between 
survival and the different variables studied were evaluated with 
the Pearson’s correlation. In all the tests, P < 0.05 was considered 
statistically significant.
Results
We confirmed that the sample of 3xTg-AD mice studied 
exhibited cognitive deficits in the MWM, mimicking the 
cognitive hallmark of AD. However, only data of animals that 
could be included in the “before–after” analysis were considered 
(animals dying in phases 1, 2, and 3 were excluded). Statistics of 
genotype effects for the different behavioral tests and variables 
studied in 3xTg-AD and NTg mice at 12 months of age (week 
1, basal, but without the segregation for the treatment they will 
receive) are cited in the text and depicted in Supplementary 
Table 1. Behavioral correlates with lifespan in animals treated 
with saline or risperidone are also indicated. Figures 1–12 depict 
the effects of chronic risperidone on these behaviors, weight, 
and survival curves of animals. Finally, Table 1 details the 
behavioral correlates with lifespan in male NTg and 3xTg-AD 
mice chronically treated with saline or risperidone.
Corner Test (CT)
Increased neophobia exhibited by 3xTg-AD mice before 
the treatment, as shown by reduced number of corners and 
rearings and increased latency of rearing, was not ameliorated 
by risperidone (Figure 1). The repeated CT allowed to observe 
a reduction of the number of corners through the treatment as 
compared to basal levels, in all groups [Figure 1A, NTg (s), t = 
3.015, gl 11, P < 0.05; NTg (r), t = 8.517, gl 10, P < 0.001; 3xTg-
AD(s), t = 2,620, gl 11, P < 0.05; 3xTg-AD(r), t = 2.776, gl 10, P < 
0.05]. Likewise, a decrease in vertical activity was observed in 
NTg (r) mice (t = 2.637, gl 10, P < 0.05) and 3xTg-AD (s) mice 
(t = 2.327, gl 11, P < 0.05) (Figure 1C). When the four groups 
were compared, genotype effects were still shown in the ”number 
of corners visited” in weeks 11 [F(1,43) = 6.623, P < 0.05] and 12 
[F(1,43) = 15,503, P < 0.001]. The latency of rearing was more 
sensitive to the genotype effect as it was observed from weeks 9 to 
12 [all F(1,43) < 14,450, P < 0.001] and showed a treatment effect 
in week 9 [F(1,43) = 4.495, P < 0.05] and interaction “genotype × 
treatment” in week 10 [F(1,43) = 7.151, P < 0.05] (Figure 1B). In 
the variable “number of rearings,” genotype effect was observed 
from weeks 8 to 12, with all the [F(1,43) < 25.961, P < 0.001] 
and interaction effect genotype × treatment in week 10 [F(1,43) = 
5.975, P < 0.05] (Figure 1C).
Open Field Test (OF)
The delayed ethogram (sequence of behavioral events), the reduced 
horizontal and vertical activities, and the increased emotionality 
behavior (urination) exhibited in the OF described an increased 
anxious-like profile in the 3xTg-AD mice. After treatment, genotype 
and treatment effects were found as detailed in Figure 2. In the 
NTg mice treated with saline, the latencies of “first movement” 
(freezing behavior) (t = 2.353, gl 11, P < 0.05) and “grooming” (t = 
2.935, gl 11, P < 0.05) were delayed as compared before treatment 
(Figures 2A, B). In addition, there was a decrease in the “total 
distance traveled” (t = 4.674, gl 11, P  < 0.01) (Figure  2E). In 
contrast, the sequence of behaviors [“first movement”, “leaving the 
center,” “entering into the periphery,” all t(10) < 14,317, P < 0.001; 
“grooming,” t = 3,681, gl 10, P < 0.01] was faster in those receiving 
risperidone. A decrease in the “total number of rearings” (t = 
2.948, gl 10, P < 0.05) was observed (Figure 2D). In the 3xTg-AD 
mice treated with saline and risperidone, the “latency to enter the 
periphery” was advanced in time (t = 3.236, gl 11, P < 0.01 and 
t = 4.071, gl 10, P < 0.01, respectively). Likewise, 3xTg-AD (r) mice 
showed a decrease in the horizontal activity “distance traveled” 
(t = 4.104, gl 10, P < 0.01) (Figure 2E) and in the vertical activity 
“total number of rearings” (t = 2.512, gl 10, P <0.05) indicating 
differences between the untreated phase and the treatment phase 
at 0.1 mg/kg (Figure 2D). When the four groups of treated animals 
were compared with each other, a genotype effect [F(1,43)  = 
20.950, P < 0.001], treatment effect [F(1,43) = 6.802, P < 0.05], 
and interaction effect “genotype × treatment” [F(1,43) = 13.161, 
P < 0.01] was detected in the variable “total distance traveled.” 
This was due to the fact that the NTg (r) mice performed greater 
horizontal exploratory activity with respect to the group of NTg 
(s) mice, while the 3xTg-AD (r) mice performed less horizontal 
activity with respect to the 3xTg-AD mice (s) (Figure 2E). In 
addition, in the variables of vertical activity, it was observed that 
the “latency of the first rearing” showed treatment effect [F(1,43) = 
4.376, P < 0.05]. Similarly, the “total number of rearings” indicated 
genotype effect [F(1,43) = 16.431, P < 0.001], treatment [F(1,43) = 
5.594, P <0.001], and interaction “genotype × treatment” [F(1,43) = 
4.410, P < 0.05] (Figures 2C, D). The variable “grooming latency” 
showed genotype effect [F(1,43) = 26.950, P < 0.001] because time 
was delayed in 3xTg-AD mice relative to the other two NTg groups. 
Regarding the variable “total number of grooming,” a “treatment 
× genotype” interaction effect was observed [F(1,43) = 8.718, 
P <0.01] due to a decrease in behavior in the groups of 3xTg-AD 
mice with respect to the other two NTg groups. In the “urine,” a 
genotype effect was observed [F(1,43) = 11.133, P < 0.01] due to 
higher incidence of urine in the 3xTg-AD groups with respect to 
the NTg groups (Figure 2F).
T-Maze (TM)
Behavioral patterns exhibited in the TM differing between 
genotypes were referred to emotionality behavior (urination), 
which was increased in the 3xTg-AD mice. As shown in 
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Figure  3, before–after differences were only shown in the 
groups of 3xTg-AD mice. Animals treated with saline showed 
an increase in the number of defecation boli (t = -4.486, gl 11, 
P < 0.01), while the 3xTg-AD (r) group needed longer “time to 
complete the maze” (t = -2.578, gl 10, P < 0.05). When the four 
groups of animals were compared with each other, the “latency 
to cross the intersection” indicated genotype effects [F(1,43) = 
5.668, P < 0.05] due to a delay in the 3xTg-AD mice with respect 
to the two groups of NTg mice. The genotype effect was also 
evidenced in the variable “exploratory activity” [F(1,43) = 4.496, 
P < 0.05] because the groups of 3xTg-AD mice performed a 
greater number of episodes with respect to the two NTg groups. 
“Genotype × treatment” interaction effects were shown in the 
“number of fecal boli” [F(1,43) = 4.930, P < 0.05] and “total 
number of urine” [F(1,43) = 11.381, P < 0.01].
Social Interaction Test (SIT)
In this test, exhibition of social (Figure 4) and non-social 
(Figure  5) behaviors were analyzed. “Face/body contact,” 
FIGURE 1 | Effects of chronic risperidone assessed in the corner test. Results in the corner test before (basal) and through different weeks of treatment. (A) Number 
of corners, (B) latency of first rearing, and (C) number of rearings. ANOVA 2×2, genotype effect (G), genotype × treatment interaction (G×T), ***p < 0.001, **p < 0.01, 
and *p < 0.05. Post hoc Tukey B test *p < 0.05 vs. all other experimental groups; ap < 0.05 vs. different genotype but the same treatment; and cp < 0.05 vs. different 
genotype and different treatment. t -test for paired data, treatment effect: treatment with a dose of 0.1 mg/kg vs. no treatment, &&&p < 0.001 and &p < 0.05.
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“anogenital contact,” “vibrant tail,” and “aggressive contact” 
presented distinct latencies of appearance and number of episodes 
depending on the genotype and were modified by treatment. Before 
treatment, reduced body/face interaction, horizontal and vertical 
exploratory behaviors but increased vibrating tail and digging 
were phenotypic characteristics of 3xTg-AD mice (Figure  4B). 
After treatment, in NTg (s) mice, the face/body contact behavior 
showed a decrease in the “total number of episodes” (t = 2.217, 
gl 11, P < 0.05) (Figure 4C). In the NTg (r) mice, it was observed 
that the “face/body” latency was delayed in time (t = 3.006, gl 10, 
P < 0.05) and the “vibrant tail” latency was advanced (t = 3.738, 
gl 10, P < 0.01) (Figure 4A). In addition, there was a decrease 
in the contact time “face/body” (t = 4.107, gl 10, P < 0.01) and 
“anogenital” (t = 3.546, gl 10, P < 0.01) and an increase in “vibrant 
tail” (t = -4.282, gl 10, P < 0.01) (Figure 4B). Likewise, there was 
a decrease in the number of episodes in “face/body” (t = 5.255, 
gl 10, P < 0.001), “anogenital” (t = 3.975, gl 10, P <0.01) and an 
increase in “vibrant tail” (t = -4.282, gl 10, P <0.01) (Figure 4C). 
The mice 3xTg-AD (s) presented a decrease in the duration 
“anogenital contact” (t = 2.520, gl 11, P < 0.05) (Figure 4B) and 
number of episodes of the “vibrant tail” behavior (t = 2.480, gl 11, 
P <0.05) (Figure 4C). The 3xTg-AD (r) mice showed statistical 
differences in the appearance of the “face/body contact” behavior 
(advancement, t = 2.754, gl 10, P < 0.05) and “vibrant tail” (delay, 
t = -4.643, gl 10, P < 0.01) (Figure 4A). These differences were 
also reflected in the duration and in the number of episodes, since 
the animals spent more time in the “face/body contact” behavior 
(t = 2.443, gl 10, P < 0.05) and it increased the number of episodes 
“face/body” and decreased the number of “vibrant tail” (t = 2.372, 
gl 10, P < 0.05) (Figures 4B, C). When comparing the four groups 
with each other, the variable “face/body contact latency” showed 
a “genotype × treatment” interaction effect [F(1,43) = 8.4428, 
P < 0.01], which was also evidenced in the variable total number 
of episodes of “face/body contact” [F(1.43)  = 9.199, P < 0.01] 
(Figures 4A, B).
In the “latency of anogenital contact,” genotype effects were 
observed [F(1,43) = 0.818, P < 0.01) with a delay in the groups 
of 3xTg-AD mice as compared to the other two NTg groups 
(Figure 4A). Conversely, “total anogenital contact time” showed 
genotype [F(1,43) = 6.766, P < 0.05], treatment [F(1,43) = 5.855, 
P < 0.05], and interaction “genotype × treatment” [F(1,43) = 
4.535, P < 0.05] effects (Figure 4B). The genotype effect was also 
FIGURE 2 | Effects of chronic risperidone assessed in the open field test. Results in the open field test before (basal) and during treatment. (A) Latencies before 
treatment; (B) latencies after treatment; (C) number of rearings; (D) total number of episodes of rearing and self-grooming; (E) total distance covered; (F) total 
number of episodes of defecation and urine. ANOVA 2×2, genotype effect (G), treatment (T) and genotype × treatment interaction (G×T), ***p < 0.001, **p < 0.01, 
and *p < 0.05. Post hoc Tukey B test ap < 0.05 vs. different genotype but the same treatment and cp < 0.05 vs. different genotype and different treatment. Effect 
t-test for paired data, treatment effect: treatment with a dose of 0.1 mg/kg vs. before treatment &&&p < 0.001, &&p < 0.01, and &p < 0.05.
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evidenced in the total number of “anogenital contact” episodes 
[F(1,43) = 9.264, P < 0.01], treatment [F(1,43) = 7.509, P < 0.01], 
and interaction [F(1,43) = 5.017, P < 0.05] (Figure 4C). This 
was due to the fact that the NTg (s) mice had greater contact 
duration and number of episodes with respect to the other three 
experimental groups. In the “tail vibration latency,” “genotype × 
treatment” interaction effect was observed [F(1,43) = 5.396, P < 
0.05] (Figure 4A). Likewise, the variable “total time” presented 
genotype effect [F(1,43) = 7.836, P < 0.01] as well as the variable 
“number of episodes” [F(1,43) = 6.949, P < 0.05] because groups 
of 3xTg-AD mice invested more time and presented an increase 
of episodes with respect to the other two NTg groups (Figures 
4B, C). In the aggressive contact component, no significant 
differences were observed in any of the three variables studied 
for this behavior (Figures 4A, B, C).
Figures 5A and B illustrate the pattern of non-social behaviors 
before and after the treatment. In the NTg mice, changes were 
only observed in those animals treated with the antipsychotic, 
with a reduced number of rearings (t = 5.519, gl 10, P < 0.001) 
and visited corners (t = 2.679, gl 10, P < 0.001) as compared to 
basal levels (Figure 5B). In the 3xTg-AD (s) mice, the “latency of 
rearing” was delayed in time (t = 2.205, gl 11, P < 0.05) resulting 
in a decrease of the “number of rearings” (t = 3.116, gl 11, P < 
0.01). This was also evidenced in the 3xTg-AD (r) mice where the 
“latency of rearing” was delayed in time (t = -2.323, gl 10, P < 0.05), 
the “number of rearings” decreased (t = 5.723, gl 10, P < 0.001) and 
FIGURE 3 | Effects of chronic risperidone assessed in the T-Maze before (basal) and during the treatment. (A) Latencies (s), (B) time to complete the maze (s), 
and (C) total number of defecations and urine. ANOVA 2×2, genotype effect (G), genotype × treatment (GxT), ***p < 0.001 and *p < 0.05. Post hoc Tukey B test 
ap < 0.05 vs. different genotype but the same treatment and cp < 0.05 vs. different genotype and different treatment. t-Test effect for paired data, treatment effect: 
treatment with a dose of 0.1 mg/kg vs. no treatment, &p < 0.05.
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FIGURE 4 | Effects of chronic risperidone in the social behaviors assessed in the social interaction test before (basal) and during the treatment. (A) Latencies (s). 
ANOVA 2×2, genotype effect (G), genotype × treatment interaction (G×T), **p < 0.01 and *p < 0.05. Post hoc Tukey B test *p < 0.05. vs. all other experimental groups; 
ap < 0.05 vs. different genotype but the same treatment and cp < 0.05 vs. different genotype and different treatment. t-test effect for paired data, treatment effect (T): 
treatment with a dose of 0.1 mg/kg vs. no treatment, &&p < 0.01 and &p < 0.05. (B) Total time and (C) total number of episodes. ANOVA 2×2, genotype effect (G) 
treatment effect (T) and genotype × treatment interaction effect (G×T), ***p<0.001 **p < 0.01 and *p < 0.05. Post hoc Tukey B test *p < 0.05. vs. all other experimental 
groups; at p < 0.05 vs. different genotype but the same treatment; bp < 0.05 vs. different treatment but the same genotype and cp < 0.05 vs. different genotype and 
different treatment. t-test effect for paired data, treatment effect: treatment with a dose of 0.1 mg/kg vs. no treatment, &&&p < 0.001, &&p < 0.01, and &p < 0.05.
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also the “number of visited corners” reduced (t = 3.264, gl 10, P < 
0.01) (Figures 5A, B). When comparing the four experimental 
groups with each other, these results were noted as genotype 
effect in the “latency of the first rearing” [F(1,43) = 24,813, P < 
0.001], “total number of rearings” [F(1,43) = 67.857, P < 0.001], 
and “total number of corners” [F(1,43) = 89.604, P < 0.001] due 
to the reduced activity of 3xTg-AD mice with respect to the two 
groups of NTg mice. The treatment effect was observed only in 
the duration of the burying, which was reduced by risperidone 
[F(1,43) = 4.185, P < 0.05] in both genotypes. No effects of the 
genotype or treatment were observed in the “grooming” variable.
Morris Water Maze (MWM)
Figure 6 depicts the before and after trial-by-trial (Figures 6A, 
B) and day-by-day (Figure 6C) place learning task acquisition 
curves as well as the platform preference shown in the probe 
trial to assess memory after treatments (Figure 6D). The trial-
by-trial performance before treatment indicated that on each 
day, except for day 3, there was an effect of the “trial” [day 1, 
F(3,144) = 9.914, P < 0.001; day 2, F(3,144) = 4.082, P < 0.01; 
day 4, F(3,144) = 7.242, P < 0.001; day 5, F(3,144) = 4.934, P < 
0.01]. However, this basal performance in the 3xTg-AD mice 
resulted in a worse day-by-day acquisition curve with higher 
latencies as compared to NTg mice, on days 3, 4, and 5. After 
treatment, statistical significant differences were only shown on 
day 1, with a “trial × genotype” [F(3,144) = 2.664, P  < 0.05] 
and “trial × genotype × treatment” [F(3,144) = 3.766, P < 0.05] 
effects. No differences in the acquisition curves were found 
among the four treated groups. When performance on this first 
day after treatment was compared to the last performance before 
treatment, only NTg (s) mice showed worsen performance 
(t = -2.239, gl 11, P < 0.05). As compared with their respective 
acquisition curves before treatment, all groups of mice were 
faster finding the platform in this re-test. NTg (s) showed 
statistical differences on days 1, 2, and 5 (all t > 2.484, gl 11, P < 
0.05), NTg (r) on days 1 and 2 (both t > 1.866, gl 10, P < 0.01), 
3xTg-AD (s) from days 1 to 4 (all t > 1.950, gl 11, P < 0.01), and 
3xTg-AD (r) on all the days (all t > 2.096, gl 11, P < 0.01).
The second paradigm consisted of the removal of the 
platform. Before treatments, NTg groups showed the highest 
number of entries in the trained quadrant, where the platform 
was previously located, with respect to the other quadrants [NTg 
(s), F(3,47) = 13.48, P < 0.001; NTg (r), F(3,43) = 9.62, P < 0.001]. 
The number of entries in the trained platform was significantly 
lower in the 3xTg-AD groups. The detailed analysis showed that 
preference was also shown for the right quadrant [3xTg-AD 
(s), F(3,47) = 8.80, P < 0.001; 3xTg-AD (r), F(3,43) = 8.14, P < 
0.001] indicating lower focused search strategies in these mice. 
After treatment, the NTg (s) mice showed an increase in the 
FIGURE 5 | Effects of chronic risperidone in the non-social behaviors assessed in the social interaction test before (basal) and during the treatment. (A) Latencies 
(s) and (B) total number. ANOVA 2×2, genotype effect (G), treatment (T), ***p < 0.001 and *p < 0.05. Post hoc Tukey B test ap < 0.05 vs. different genotype but the 
same treatment and cp < 0.05 vs. different genotype and different treatment. Effect t-test for paired data, treatment effect: treatment with a dose of 0.1 mg/kg vs. 
untreated &&&p < 0.001, &&p < 0.01, and &p < 0.05.
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number of entries in the “trained quadrant” with respect to the 
other quadrants [F(3,47) = 18.91, P < 0.001]. In contrast, in the 
other treated groups, an increase in entries was observed in both 
the quadrant of the platform and the right quadrant [NTg (r), 
F(3,43) = 31.18, P < 0.001; 3xTg-AD (s), F(3,47) = 18.91, P < 
0.001; 3xTg-AD (r) [F(3,43) = 15.27, P < 0.001]. Thus, the variable 
“number of entries in the right quadrant” indicated “genotype × 
treatment” interaction effect [F(1,43) = 19.401, P  < 0.001]. As 
compared to their respective performances before treatment, 
statistical differences were only found in the NTg (r) mice, as a 
decrease in the number of entries in the opposite (t = 3.203, gl 10, 
P < 0.01) and left (t = 3.909, gl 10, P < 0.01) quadrant.
Marble Burying Test (MB)
As illustrated in Figure 7, before treatment, 3xTg-AD mice 
showed an increased pattern of interaction with marbles, with 
a higher number of marbles that changed position and were 
buried than NTg counterparts. After treatment NTg (s) mice 
the “intact” marbles were the least frequent compared to the 
marbles that changed position and were buried [F(2,35) = 
19.51, P < 0.001]. Oppositely, in NTg (r) mice, an increase in the 
number of marbles “intact” and a decrease in “buried” marbles 
[F(2,32) = 13.05, P < 0.001] was observed. In the two groups of 
treated 3xTg-AD mice, no significant changes were observed 
between the three levels of interaction with marbles. In each 
group, before and after comparisons indicated differences: NTg 
(s) mice, in the marble number variables “intact” (t = 5.348, gl 
11, P < 0.001) and “buried” (t = -3.824, gl 11, P < 0.001) because 
after the treatment, there was a decrease in the number of intact 
marbles and an increase in the number of marbles buried. In 
the 3xTg-AD (s) mice, an increase in the number of “changed 
position” marble was observed (t = -2.601, gl 11, P < 0.05) and 
a decrease in “buried” marble (t = 3.348, gl 11, P < 0.01). In the 
groups of animals treated with risperidone NTg (r) and 3xTg-AD 
(r), no changes were observed. Treatment effects were shown in 
the “number of intact marble” [F(1,43) = 7.802, P < 0.01] as an 
increase in its number in the groups treated with risperidone 
compared to those treated with saline. Conversely, the “number 
of buried marbles” also indicated treatment effect [F(1,43) = 
8.573, P < 0.01] with a reduction as compared to those treated 
with saline, although this decrease is only significant in the case 
of NTg (r) animals. Furthermore, in this variable, the interaction 
effect ”genotype × treatment” was observed [F(1,43) = 6.114, P < 
0.05] due to a decrease in the number of marbles buried in the 
NTg (r) mice and an increase in the 3xTg-AD (r) mice.
Baseline State of Blood Glucose
Basal state of glucose levels before treatment did not differ 
between 3xTg-AD and NTg mice (Figure 8). However, after 
treatment, NTg (r) mice showed a marked decrease (t = 7.611, 
gl 11, P < 0.001). This led to a ”genotype × treatment” effect 
[F(1,43) = 9.441, P < 0.01].
FIGURE 6 | Effects of chronic risperidone in the Morris water maze before (basal) and during the treatment genotype effect (G). Latencies (s) evolution before 
(A) and after (B) the treatment, evolution of learning and memory, trial by trial for each of the 5 days. Repeated measures ANOVA, 2×2×5, day effect (D), day × 
genotype effect (DxG), and interaction effect (D×G×T), *p < 0.05, **p < 0.01, and ***p < 0.001. Post hoc Tukey B test ap < 0.05 vs. different genotype but the same 
treatment and cp < 0.05 vs. different genotype and different treatment. t-Test for paired data, treatment effect: trial 1 of day 1 with treatment vs. trial 4 of day 5 
without treatment, &p < 0.05. (C) Latency (s), evolution of learning and memory day by day. Repeated measures ANOVA 2×2×5, ns and post- hoc Tukey B test, 
ns (D) total number of entries in the quadrant: platform (P), right (Ar), opposite (O), and left (Al). ANOVA 2×2, genotype × treatment interaction effect (G×T), ***p < 
0.001. t-Test for paired data, treatment effect: treatment with a dose of 0.1 mg/kg vs no treatment, &&p < 0.01 and &p < 0.05. ANOVA and post hoc Tukey B test 
interaction of the three levels #p < 0.001.
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Weight
The body weight (BW) of animals was monitored throughout 
the experimental procedures (Figure 9). At the beginning 
of the experiments, weight of 3xTg-AD mice was higher than 
that of controls (t = -2.213, gl 50, P < 0.05), but differences were 
attenuated through the experiments. Statistical significance 
was lost in week 6, just before treatment started (NTg mice, t = 
4.035, gl 23, P < 0.01; 3xTg-AD mice, t = 6.234, gl 27, P < 0.001). 
During the first week of treatment (risperidone, 0.05 mg/kg), all 
the groups lost weight [NTg (r) mice, t = 2.965, gl 10, P < 0.05; 
3xTg-AD (s), t = 2.718, gl 11, P < 0.05; 3xTg-AD (r), t = 4.633, 
gl 10, P < 0.01] except NTg mice treated with saline. At 10 weeks 
FIGURE 7 | Effects of chronic risperidone in the marble burying test before (basal) and during the treatment. Number of marbles. t-Test for paired data, treatment 
effect: treatment with a dose of 0.1 mg/kg vs no treatment, &&&p < 0.001, &&p < 0.01, and &p < 0.05. ANOVA and post hoc Tukey B test interaction of the three levels 
#p < 0.001. ANOVA 2×2, (T), treatment effect and (G×T), genotype × treatment interaction, ***p < 0.001, **p < 0.01, and *p < 0.05. Post hoc Tukey B test bp < 0.05 
vs. different treatment but the same genotype and cp < 0.05 vs. different genotype and different treatment.
FIGURE 8 | Effects of chronic risperidone in basal state of glucose before and during the treatment. t-Test for paired data, treatment effect: treatment with a dose 
of 0.1 mg/kg vs no treatment, &&&p < 0.001. ANOVA 2×2, interaction effect genotype × treatment (G×T), **p < 0.01. Post hoc Tukey B test bp < 0.05 vs. different 
treatment but the same genotype.
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FIGURE 9 | Effects of chronic risperidone in the body weights of the animals before (basal), during the treatment, and immediately after death Phase 1 Basal. 
Student’s t-test; *p < 0.05. Phase 2. Start of treatment with risperidone at a dose of 0.05 mg/kg. Weights. t-Test for paired data, treatment effect: treatment with 
a dose of 0. 05 mg/kg vs untreated, &&p < 0.01 &p < 0.05 for Phase 3. Treatment with risperidone at a dose of 0.1 mg/kg. t-Test for paired data, treatment effect: 
treatment with a dose of 0. 1 ml/kg vs untreated &&p < 0.01 &p < 0.05 Phase 4. Immediately after death vs. the weights at the beginning of the longitudinal study. 
t-Test for paired data &&p < 0.01, and &p < 0.05.
FIGURE 10 | Effects of chronic risperidone in the total mean survival. Mean ± SEM. Survival curves based on the age of the animals (in days). Each line represents 
the cumulative survival of the animals of each experimental group [NTg (s) and 3xTg-AD (s)] Log-rank test p < 0.001. Survival curve based on the age of the animals 
(in days). Each line represents the cumulative survival of the animals of each experimental group [NTg (s), NTg (r), 3xTg-AD (s) and 3xTg-AD (r)]. Log-rank-test  
###p < 0.001.
Early Mortality Risk by AntipsychoticsTorres-Lista et al.
14 September 2019 | Volume 10 | Article 1061Frontiers in Pharmacology | www.frontiersin.org
of treatment (risperidone, 0.1 mg/kg), the loss of weight was 
only observable in the 3xTg-AD mice [3xTg-AD (s), t = 2.312, 
gl 11, P < 0.05; 3xTg-AD (r), t = 3.478, gl 11, P < 0.01]. The four 
experimental groups showed reduced “weight immediately after 
death” as compared to before treatment [NTg (s), t = 2.209, gl 
11, P < 0.05; NTg (r), t = 5.382, gl 10, P < 0.0 01; 3xTg-AD (s), 
t = 5.721, gl 11, P < 0.001; 3xTg-AD (r), t = 3.937, gl 10, P < 
0.01]. When the four groups of animals were compared with each 
other, no differences were found among them at either of both 
time points.
Survival Curve
Figure 10 illustrates the survival curves and lifespan, which 
differed among the groups: NTg (s): 1.078 days (36 months), NTg 
(r): 874 days (28 months), 3xTg-AD (s): 768 days (24 months), 
3xTg-AD (r): 660 days (22 months), with a genotype effect in 
mean lifespan. Lifespan was reduced by AD genotype [F(1,48) = 
24.812, P < 0.001] but also by risperidone treatment (shortened 2 
months in 3xTg-AD but in 8 months in NTg mice). Survival curves 
showed that until 14 months of age, all groups exhibited 100% 
survival. Thereafter, only NTg (s) mice maintained its survival 
intact until 19 months, that is, 5 months longer than the other 
groups. When comparing the four groups, their mean survival at 
15 months of age showed a genotype [F(1,45) = 4.968, P < 0.05] 
and “genotype × treatment” [F(1,45) = 4.968, P < 0.05] interaction 
effects. Thus, although onset of mortality window was 15 months 
for NTg (r), 3xTg-AD (s), and 3xTg-AD (r), the different slopes 
in their survival curves indicated different severity levels: 
NTg (r), survival of 91.61%, 3xTg-AD (s), survival of 85.71%, 
3xTg-AD (r), 78.48% (Figure 11). Average life expectancy (50% 
survival) differed among the four groups [F(3,28) = 262.25, P < 
0.001]. In NTg mice, the average life expectancy was 24 months, 
whereas in the two groups of 3xTg-AD mice, it was 18 months. 
Likewise, when 25% of the survival was analyzed, statistically 
significant differences with respect to the group of NTg (s) mice 
[F(3,12) = 137.41, P < 0.001] were found. The Kaplan-Meier test 
showed significant differences between 3xTg-AD (s) and NTg 
(s) (Log rank = 7.218, gl 1, P < 0.01) and also among the four 
experimental groups (Log rank = 22.833, gl 1, P < 0.001).
Table 1 summarizes the meaningful correlation analysis 
of lifespan with the behavioral phenotype before and after 
treatment with risperidone for each one of the four experimental 
groups, while Figure 12 illustrates the correlations with the 
whole sample of 46 animals. As shown, in most tests, freezing 
behavior and activity to complete the task were strongly (P < 
0.01) correlated with lifespan in NTg (s). In the NTg (r), it was 
mostly related to the elicitation of emotionality (grooming), 
vertical exploratory activity (rearing), and agonistic behaviors 
(body face, inversely with vibrating tail). Poorest behavioral 
correlates were found in 3xTg-AD mice, where survival 
was inversely correlated to a poor marble burying, scarce 
and slow exploratory activity, and presence of vibrating 
tail. Survival in 3xTg-AD (r) was negatively correlated with 
delay in the elicitation of vertical exploratory activity and 
number of groomings. Correlation with cognitive task was 
only shown in NTg(s), while the tests and/or variables with 
predictive value in the whole sample were those related to the 
BPSD-like phenotype.
DISCUSSION
The main objective of the present work was to model in 
3xTg-AD mice the increased mortality risk induced by the 
chronic administration of the atypical antipsychotic risperidone 
shown in patients with AD. This is the first study that considers 
this objective despite the imperative need to have an animal 
modeling this vulnerability, an issue that cannot be addressed 
in clinical studies.
Experimental design. First, the battery of behavioral tests 
allowed us to confirm the AD phenotype of the animals (Giménez-
Llort et al., 2007). Thus, we verified the existence of cognitive 
and BPSD-like behaviors in this initial sample of middle-aged 
3xTg-AD mice, an age that has extensively been described 
to mimic advanced neuropathological stages of the disease 
FIGURE 11 | Effects of chronic risperidone in the total mean survival. Mean ± 
SEM. ANOVA and post hoc Tukey B test ***p<0.001, ap < 0.05 vs. same 
treatment but different genotype, bp < 0.05 vs. different treatment but the 
same genotype and cp < 0.05 vs. different treatment different genotype.
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FIGURE 12 | Behavioral correlates for lifespan considering all the sample of animals. Pearson’s correlations between behavioral variables and lifespan: *p < 0.05,  
**p < 0.01.
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(Belfiore et al., 2019). Here it is important to note that although 
the cognitive deficits in the MWM were confirmed, the inclusion 
criteria in the “before–after treatment” analysis excluded the 
animals that died during the period of behavioral assessments. 
In AD, treatments with atypical antipsychotics are effective in 
controlling anger, agitation, aggression, and symptoms more 
typical of the psychotic spectrum such as hallucinations, paranoia, 
and delusions, while cognitive symptoms, quality of life, and 
attention do not improve with these treatments (Kalman et al., 
2008). In view of the pharmacological action of the antipsychotic 
treatment, it is therefore interesting to note that the animals 
before treatment had cognitive deficits but also an increase in the 
stereotyped behavior of marble burying (usually used to assess 
the efficacy of antipsychotics) and alterations in social behavior 
(also modifiable with antipsychotics). Once the phenotype was 
verified, we evaluated the response of 3xTg-AD mice to chronic 
treatment with risperidone as compared to the effects exerted 
on age-matched NTg mice but also as compared to their own 
phenotype before treatment. Risperidone was used at a dose of 
0.1 mg/kg equivalent to those administered in patients with AD 
and used in most experimental work performed in rodents. As in 
the case of geriatric patients, the treatment regimen was initiated 
with a lower dose of 0.05 mg/kg.
In the longitudinal study, the baseline characterization was 
performed at 12 months of age and the administration of the 
treatment started at 13 months, which in both cases corresponds 
to advanced neuropathological stages of the disease. The number 
of animals used (n = 12–14 for each group) was adequate for 
behavioral studies according to the guidelines on the use of 
genetically mutated animals and taking into account that at 
the middle age, the individual variability increases due to age. 
However, for the study of long-term survival curves, it would 
have been advisable to use a much greater number, between 40 
and 50 animals. This and other works of the literature are limited 
TABLE 1 | Behavioral correlates with lifespan in male NTg and 3xTg-AD mice chronically treated with saline or risperidone.
Behavioral test and variable Lifespan (days)
NTg(s) NTg(r) 3xTg-AD(s) 3xTg-AD(r)
Before treatment.
Corner Test 
Vertical activity (latency, s) 0.684* n.s. n.s. n.s.
Vertical activity (number) -0.614* n.s. n.s. n.s.
Open field test 
Initial movement (latency of freezing, s) 0.715** n.s. n.s. n.s.
Exist of the center (latency, s) 0.63** n.s. n.s. n.s.
Vertical activity (latency, s) n.s. n.s. n.s. -0.606*
Self-grooming (latency, s) n.s. n.s. n.s. n.s.
Vertical activity (3 min) n.s. n.s. n.s. n.s.
Vertical activity (5 min) n.s. n.s. n.s. n.s.
Self-grooming (number) n.s. n.s. -0.657*
T-maze test 
Initial movement (latency of freezing, s) 0.721** n.s. n.s. n.s.
Complete the test (total time, s) 0.751** n.s. n.s. n.s.
Social Interaction Test
Non-social interactions n.s.
Self-grooming (latency, s) n.s. -0.716** n.s. n.s.
Marble interaction test
Intact (number of marbles) n.s. n.s. -0.707** n.s.
Morris water maze
Day 4 (mean latency, s) 0.684* n.s. n.s. n.s.
After treatment.
Corner Test 
Vertical activity (latency, s) n.s. n.s. 0.633** n.s.
Vertical activity (number) n.s. 0.594* -0.734** n.s.
Open field test 
Initial movement (latency of freezing, s) 0.724** n.s. n.s. n.s.
Exist of the center (latency, s) 0.734** n.s. n.s. n.s.
Entrance to the periphery (latency, s) 0.713** n.s. n.s. n.s.
T-maze test 
Initial movement (latency of freezing, s) n.s. n.s. -0.687** n.s.
Complete the test (total time, s) n.s. -0.653* n.s. n.s.
Social Interaction Test
Social interactions
Body/face (latency, s) n.s. -0.599* n.s. n.s.
Vibrating tail (latency, s) n.s. 0.611* n.s. n.s.
Vibrating tail (total time) n.s. -0.611* n.s. n.s.
Vibrating tail (total no. of episodes) n.s. 0.611* n.s. n.s.
Pearson’s correlations, *P < 0.05, **P < 0.01. n.s., non significant.
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experimentally to use a reduced number of animals by the 
difficulty of obtaining the experimental subjects.
Corner test. In the modeling of the behavioral effects 
induced by the atypical antipsychotic risperidone, the behavior 
of neophobia was evaluated by the CT. At the beginning of 
the treatment, the 3xTg-AD mice showed a greater behavioral 
inhibition when confronting novelty, presenting higher levels of 
neophobia with respect to the NTg mice, in the three variables of 
the test. Although this response was independent of treatment, 
it was observed that in NTg (r) mice, the dose of 0.05 mg/kg 
of risperidone induced a significant increase in vertical activity 
with respect to the other three experimental groups. In the 
following week (week 8, dose of 0.1 mg/kg), an attenuation of the 
differences between genotypes was observed, now only detectable 
in the rearing variable. In fact, in general, during the rest of 
the weeks, vertical behavior was the most sensitive to indicate 
the effects of the factors studied. Repeatedly, the predominant 
factor was genotype, corroborating the neophobia described in 
our laboratory in 3xTg-AD mice (Giménez-Llort et al., 2006; 
Giménez-Llort et al., 2007; Giménez-Llort et al., 2008 and 
Giménez-Llort et al., 2010), and in a few cases, treatment effect 
was observed. Therefore, chronic treatment with risperidone did 
not modify the neophobic response of the 3xTg-AD mice, and if 
any effect had, it was sporadically in NTg animals.
Open-field test. In agreement with the increased neophobia 
in the CT, in the OF to assess exploratory activity and anxiety, 
AD genotype differences were also observed with reduction of 
vertical and horizontal activity, temporal delay of the grooming 
behavior, and increased presence of urine. This predominant 
effect of the genotype factor corroborates the results obtained 
in the open field in the pretreatment phase and the CTs. Both 
the corner and open-field tests converged to show the emotional 
and anxious-like profile of 3xTg-AD mice, in agreement with our 
previous studies describing the appearance of these behaviors 
(Giménez-Llort et al., 2007; Giménez-Llort et al., 2008; Giménez-
Llort et al., 2010; Giménez-Llort et al., 2018; García-Mesa et al., 
2011; García-Mesa et al., 2012) since the early stages to advanced 
stages of the disease (Giménez-Llort et al., 2006).
The activity variables, both horizontal and vertical, also 
showed treatment effect per se and their effects were influenced 
by the interaction with the genotype. Thus, most of the effects 
of risperidone were observed again in NTg (r) animals as an 
increase with respect to the other three experimental groups. 
This seems to be a pattern similar to that observed in the CT, but 
in both horizontal and vertical vectors of locomotor activity, with 
the NTg (r) group being different from all the others.
When comparing the data at the longitudinal level, it can be 
seen that in the treatment phase, there is an attenuation of all the 
responses that could be due to the simple fact of the repetition of 
the test. Also, it could be attributed to the repeated manipulation or 
handling of animals. In both cases, these are some of the limitations 
inherent to the use of behavioral batteries and are enhanced in 
longitudinal studies and chronic treatments. These limitations are 
difficult to avoid but can be mitigated by reducing the number of 
tests and the use of tests with variables with convergent validity, as 
we have done in our study, and the selection of guidelines for oral 
administration or subcutaneous pumps.
Risperidone enhanced the behavioral differences but did so 
differently depending on the genotype. Although the differences 
between the two groups of NTg animals before the use of drugs 
may be potentiating this contrast of NTg (r) mice, we have 
verified that this group, but not the one that would be treated 
with saline, is the one that shows the most standard values 
described for the NTg male animals of our colonies. Therefore, 
in any case, the results of NTg mice treated with saline are 
downward biased.
About the effect of risperidone, studies with other mouse 
models for other pathologies, such as the ICR mouse, have found 
that a low dose of risperidone (0.01 mg/kg, i.p.) decreases the 
freezing or freezing behavior, and at high doses (0.04 mg/kg, i.p.), 
spontaneous motor activity is reduced. However, when 
co-administered with other drugs, it loses effectiveness in its 
anxiolytic effect (Miyamoto et al., 2004). In male ddY mice 
of 5 weeks of age, risperidone at a dose of 0.1 mg/kg inhibits 
methamphetamine-induced hyperlocomotion and at several 
other doses attenuates that induced by MK-801 through 
blockade of the 5-HT2A/2C receptor (Uchida et al., 2009). In 
BTBR mice at doses of 0.125 and 0.25 mg/kg i.p., risperidone 
decreases exploratory activity (total distance traveled) in the 
OF (Silverman et al., 2010). The data confirm the dopaminergic 
action of the drug modulating motor and motivational functions 
(Rinaldi et al., 2007) and exerting anxiolytic properties.
On the other hand, the literature also suggests that atypical 
antipsychotics such as risperidone could be useful in attenuating 
stereotyped behaviors and not just locomotor activity. In the 
open field, grooming behavior also showed genotype and 
genotype interaction effects by treatment. Grooming is an 
activity of daily life linked to hygiene of animals but is also 
part of copying with stress strategies, and can be developed as 
a stereotyped behavior that gives and looks easily modified 
in anxious situations (Kalueff and Tuohimaa, 2004a, Kalueff 
and Tuohimaa, 2004b). Furthermore, the grooming is used 
experimentally as a tool to measure behavioral stimulation of 
D1 receptors (Rimondini et al., 1998) so that risperidone, as 
regards its antagonist action D1, could induce a decrease in this 
behavior. In this respect, in the 3xTg-AD mice, it was observed 
that the grooming behavior appeared later in time with respect 
to its NTg control, thus corroborating the genotypic differences 
in the anxious-like profile of these animals described in our 
laboratory (Giménez-Llort et al., 2006). In these previous studies 
with old male and female 3xTg-AD mice, the grooming behavior 
appears later than in the NTg mice and, in turn, aging reduces 
the duration (Giménez-Llort et al., 2008). Regarding the effect of 
the treatment, the effects of interaction with the genotype are due 
to a more frequent grooming behavior in the NTg (r) group of 
mice, although this selective difference replicates the existing one 
before treatment. In fact, work on strains of standard mice such 
as Swiss albino mice indicates that risperidone, at doses of 0.1 
and 0.2 mg/kg, decreases the number of grooming (De Oliveira 
et al., 2008). Similarly, in the BTBR mouse model for autism, they 
have also observed that at doses of 0.125 and 0.25 mg/kg i.p. they 
reduce grooming by 40% to 50% with respect to their control, 
although the reduction in behavior can be confused with levels 
of sedation (Silverman et al., 2010).
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Social interaction test. The SIT was found the most complete 
and sensitive tests to evaluate the deficits of social behavior 
among 3xTg-AD mice in comparison with those observed 
among NTg mice of the same age and sex (Torres-Lista and 
Giménez-Llort, 2019). Here, in the basal characterization before 
treatment, we replicated the results but, this time, evaluated 
within a behavioral battery. The 3xTg-AD mice showed results 
similar to those of the NTg animals in the most common social 
interaction behavior such as body-face contact. However, the 
genotype effects indicated less anogenital contact, greater vibrant 
tail, and absence of aggressiveness in groups of 3xTg-AD mice 
with respect to what was observed among NTg mice. Besides, 
the effect of chronic treatment with risperidone was evaluated 
in these behaviors since atypical antipsychotics are often chosen 
to treat BPSD symptoms, such as psychosis, aggression, and 
agitation. Risperidone exerted effects decreasing the anogenital 
behavior and in the case of the 3xTg-AD mice, it significantly 
corrected the preponderance of the vibrant behavior recently 
described as a characteristic of the social interaction pattern of 
female 3xTg-AD mice (Torres-Lista and Giménez-Llort, 2019). 
The effects of risperidone interacted with genotype in several 
variables of social behaviors studied, in such a way that the 
effects were more intense in the NTg genotype where risperidone 
decreased social behaviors, bringing them to levels equivalent to 
those 3xTg-AD groups.
Among the non-social behaviors that appear interspersed 
during the development of social interactions, the effects of 
the genotype were observed as a decrease in the horizontal 
and vertical exploratory activity in the groups of 3xTg-AD 
mice with respect to the NTg groups. In fact, the behavior 
of vibrant tail is associated with an immobility of the animal, 
so that the highest levels of this behavior in the 3xTg-AD mice 
justify that the exploratory activity, which usually is already lower 
in these animals, be significantly reduced.
The effects of risperidone were observed only in the variable 
number of burials, where the drug decreased this behavior, 
considered mimicking psychotic type stereotypies or obsessive-
compulsive type anxiety. The improvement in this variable 
in both genotypes and the improvement also of the behavior 
of vibrant tail in the 3xTg-AD mice suggest that risperidone 
mainly exerted an antipsychotic/anxiolytic management effect, 
modifying the features of the anxious trait and/or anxious states, 
in both genotypes, respectively.
While the effects of atypical antipsychotics in exploratory 
activity and emotionality are discussed by the scientific community 
as mainly due to their dopaminergic actions, it is considered that the 
treatment with risperidone could modify the pattern of the social 
behavior thanks to its profile as a 5-HT2 antagonist, since these 
serotonergic receptors have been implicated in social interaction 
behavior (File and Seth, 2003). In a comparative study in APP/
London mice, treatment with risperidone decreased its aggressive 
behavior and did so consistently to that exerted by 8-OH-DPAT 
and buspirone, two serotonergic agonists (Moechars et al., 1998). 
In other models for AD, such as the APP23 mice, treatment with 
risperidone also attenuates the aggressive behavior of animals 
(Vloeberghs et al., 2008) whereas in psychosis models, the 
deterioration of social interaction induced by PCP can be improved 
with anticholinesterase galantamine (0.3 mg/kg) and with 0.1 mg/
kg of risperidone (Wang et al., 2007). Risperidone also corrects the 
aggression induced by social isolation in male ddY mice (Uchida 
et al., 2009) and the attack behavior in male albino mice, although 
it is not exempt from side effects at the level of motor behavior 
(Rodríguez-Arias et al., 1998). In our animal model, we observed 
spontaneous increase aggressiveness in 3xTg-AD mice1. However, 
in this study, the presence of this behavior in mice was very low or 
nonexistent, since it is spontaneous aggressiveness and not induced/
enhanced by isolation (animals start from a daily social condition). 
Even so, the aggressiveness observed in the NTg (s) mice is corrected 
in the group treated with risperidone NTg (r). In the case of 
3xTg-AD mice, it is likely that1 the behavior of “vibrant tail” acts as 
a dissipating mechanism that temporarily attenuates the response 
of directed aggressiveness, with no “aggressiveness” observed.
T-maze. The spontaneous alternation in the TM is a paradigm 
mostly used to evaluate working memory, which also includes 
aspects such as exploratory activity and emotionality/anxiety. It 
is a test based on the possibility that the rodent chooses one of 
the arms arranged in a T-shape. Many brain areas, such as the 
hippocampus, septum, prefrontal cortex, and the basal forebrain, 
as well as several neurotransmitters, such as dopamine and 
norepinephrine, are involved in the implicit working memory 
involved in the performance of the test (Zhang et al., 2004; 
Deacon and Rawlins, 2006). Variables such as latency to cross the 
intersection of the maze allow, in addition, to assess the copying 
with stress strategies of animals, this being a variable that correlates 
with a worse neuroimmunoendocrine function, indicators of 
accelerated aging in mice, and premature death (Guayerbas 
et al., 2001). In our study, no differences were observed in the 
number of execution errors, but the efficiency to complete the 
different phases of the test was diminished in 3xTg-AD mice and 
slightly affected by risperidone. Thus, in phase 2 of the study, the 
genotype effects were observed in the emotionality as an increase 
in the presence of urine with respect to the NTg groups. Later, in 
phase 3, the variable latency to intersection and time to complete 
the maze denoted the deficiencies of the 3xTg-AD.
The effects of the treatment were only observed in phase 
2, in which the groups treated with risperidone at the dose 
of 0.05 mg/kg needed more time to complete the exploration 
of the maze with respect to the groups that received saline. 
In addition, in the 3xTg-AD (r) mice, the time to complete 
the maze was also higher compared to that needed before 
treatment. The effects of the interaction between genotype and 
treatment were observed in phase 3 at the emotional level in 
both bowel movements and urine.
In our previous studies, we have observed that the latency 
to cross the intersection is a variable that reflects changes and 
subsequent deficiencies in the stress management strategies of 
animals and is related to the deterioration of the homeostasis 
of the neuroimmunoendocrine system, due to the age itself 
and, above all, in the presence of transgenes (Giménez-Llort 
et al., 2010; Giménez-Llort et al., 2012). In 6-month-old female 
3xTg-AD mice, these changes are reflected as a greater speed to 
1Ramírez-Boix, P., and Giménez-Llort, L. (submitted). Modeling BPSD in rodents: 
relevance of spontaneous aggressiveness and chronic mild social stress.
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reach the intersection of the TM with respect to the controls in 
a typical flight behavior, while at later ages, the strategy fight-
or-flight chosen to combat the acute stressful situation is the 
petrifaction (Giménez-Llort et al., 2010, Giménez-Llort et  al., 
2012). These observations agree with those of the reference 
laboratory that described this functional relationship in a 
longitudinal study with female OF-1 Swiss mice. Thus, De la 
Fuente’s laboratory showed that the animals that spend more 
time in the TM show high levels of emotionality/anxiety and 
have a less competent immune system with respect to those that 
explore more quickly. In addition, the animals that showed lower 
performance in the TM showed a reduction in survival compared 
to those that obtained better results (Guayerbas et al., 2001).
The decrease of spontaneous alternation in the TM has also 
been observed in other transgenic models of AD such as Tg2576 
(Lalonde et al., 2003) and APP/PS1 (Tempier et al., 2013) 
mice, in animal models for schizophrenia as STOP-null mice 
(Delotterie et al., 2010), or pharmacological models by selective 
blockade of dopamine D1 and D2 receptors in the pre-limbic 
region of the prefrontal cortex (Rinaldi et al., 2007). The effects 
of antipsychotics differ depending on the model, the drug, and 
the duration of treatment. Thus, in APP/PS1 mice, the chronic 
treatment with Quetiapine for 7 and/or 10 months normalized 
the anxiety-like behavior observed in the maze, minimized 
memory deterioration, and decreased Aβ plaques in the brain. 
In the STOP-null mice, treatment with risperidone only induced 
a trend to reduce the spontaneous alternation in the Y-maze 
(Delotterie et al., 2010). Other work in the radial maze has shown 
beneficial effects of olanzapine and clozapine on the memory 
impairment of male BALB/c mice, although they were not 
exempt from some extrapyramidal effects (Mutlu et al., 2012).
Together with the CT and the open field, the results in the TM 
provided new data to confirm the emotional/anxious-like profile 
of the 3xTg-AD mice and their worse capacity to cope with 
stress; however, it did not show problems in working memory 
as measured by spontaneous alternation. The chronic treatment 
with risperidone, in any case, worsened this AD-profile and 
the exploratory efficiency of NTg animals, probably due to the 
extrapyramidal effects. Still, being an atypical antipsychotic and 
administered in a low dose regime, it is considered that these side 
effects are much lower than in other classic antipsychotics.
Morris water maze. To evaluate short- and long-term spatial 
reference learning and memory, the MWM was used (Morris, 
1981; Morris, 1984). All groups showed the same acquisition 
curve in either the “trial-by-trial” or the “day-by-day” analysis 
for short-term and long-term learning and memory, respectively. 
Likewise, in the probe trial with removal of the platform, all the 
groups distinguished the quadrant of the platform with respect 
to the other quadrants, although the risperidone treatment 
decreased the selective search of the platform incorporating one 
of the adjacent quadrants in the preference. The preference of 
this adjacent area indicates less focused goal-directed swimming 
strategies (Baeta-Corral and Giménez-Llort, 2015). The 
interaction between genotype and treatment in the preferences 
of the two adjacent quadrants indicated that the effects of 
risperidone affect the two genotypes differently, although in 
general these and the other data do not indicate deficiencies 
per se but rather changes in search strategies. Thus, as in the 
case of working memory, risperidone did not affect the results 
decisively since the animals continued to distinguish what had 
been the position of the platform. It should also be noted that the 
parity in the results of this test is surely conditioned by the fact 
of the previous knowledge of the paradigms since the genotype 
differences that were observed in the first experience in the water 
maze no longer exist among the saline groups. The latencies to 
reach the platform in the first trials were very low, equivalent 
to the third day of testing before treatment, supporting this 
interpretation. Here, it is important to remind that the analysis 
is based on a “before–after design” on censured data, that is, 
excluding the animals that died during phases 1, 2, and 3. Since 
the performance of the initial sample of animals was in agreement 
with the cognitive deficits described in this animal model at 12 
months of age, the present results in the before–after analysis 
suggest a mortality bias, with exclusion of animals with worse 
life prognostic as determinant to the deficits in the overall group 
performance. Also, this suggests that the effects of risperidone 
illustrated here were those exerted in the “less worse” animals, as 
those that died during the behavioral assessments were excluded.
In some cases, in this mouse model, it has also been observed 
that the treatments, according to their pharmacological 
actions, selectively affect different aspects of the learning and 
memory process. This is the case of the study with 10-month-
old 3xTg-AD mice in both sexes, where it was found that the 
chronic treatment of 5 months with paroxetine improved the 
deficit of the space navigation in both males and females, without 
affecting the speed of swimming or the distance traveled, which 
suggests a conservation of cognitive functions (Nelson et al., 
2007). Likewise, studies with 12-month-old female 3xTg-AD 
mice treated with melatonin found that the treatment improved 
learning retention from platform position (García-Mesa et al., 
2012). In APP/PS1 mice treated with quetiapine, the continuous 
administration of 4 to 7 months of the antipsychotic decreased the 
number of plaques of Aβ in the cortex and in the hippocampus 
of the animals and reduced memory loss, also attenuating the 
anxiety-like behavior (He et al., 2009). On the other hand, it has 
been described that olanzapine does not affect the processes of 
acquisition, consolidation, or recovery in the MWM test (Hou 
et al., 2006). However, the same work shows that clozapine 
and haloperidol appeared to affect the acquisition process and 
consolidation and induced a deterioration in spatial learning 
(Hou et al., 2006).
In fact, the effects of antipsychotics on learning and memory 
in processes that occur properly with psychosis are controversial, 
since there are studies in rats that have indicated that the 
classic antipsychotic haloperidol and the atypical antipsychotic 
risperidone, at certain doses, affect cognitive processes (Didriksen 
et al., 2007), while clozapine and sertindole were effective in the 
treatment of psychosis without producing detrimental effects 
on cognition (Mutlu et al., 2012). It is more than probable that 
these discrepancies in the pharmacological actions are due to 
the differences they present in the profile of pharmacological 
selectivity by different neurotransmission systems such as 
dopamine and serotonin. In this respect, risperidone is classified 
as a “qualitatively atypical” antipsychotic agent with a relatively low 
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incidence of extrapyramidal effects when given at low doses that 
have a serotonergic antagonist action higher than dopaminergic.
Marble burying test. The burial test for marbles, which is 
used for the detection of new antidepressants, anxiolytics, and 
antipsychotics (Njung’e and Handley, 1991; Bruins Slot et al., 2005 
and Kaurav et al., 2012), was found sensitive to detect alterations 
in the 3xTg-AD mice (Torres-Lista et al., 2015). The response 
patterns were clearly different, since the level of interaction of 
the NTg mice with the marbles results in half of the objects being 
changed of position, while the other two quarters remained 
intact or have been buried. In the 3xTg-AD mice, the burying 
behavior is enhanced so that more than half of the objects appear 
buried at the end of the test, a quarter changed position, and only 
the remaining 10% remained intact.
The marble burying behavior of marbles was studied again to 
evaluate the effect of the antipsychotic. However, it is interesting 
to observe previously, in the results of the groups treated with 
saline, that the behavioral pattern described above for one and 
another genotype has been significantly modified by the protocol 
of chronic manipulation. In the NTg mice, the interaction with 
the objects increased, enhancing the burying of the marbles, 
which are now quantitatively equivalent to the marbles that 
changed position. In contrast, in 3xTg-AD mice, chronic saline 
treatment reduced the interaction with the objects, significantly 
decreasing the number of marbles buried in favor of the marbles 
that changed position. Taken together, these effects reduce 
genotype differences.
When all the factors are evaluated together, the observation of 
the absence of genotype effect is ratified. Risperidone increased the 
number of marbles intact and decreased the number of marbles 
buried with respect to the groups administered with saline, so, 
in general, risperidone reduced the interaction with objects. 
These results corroborate those observed in the burying/digging 
behavior during the SITs. Converging, differences were also found 
between genotypes with greater burying behavior in the 3xTg-AD 
mice, the genotype differences disappeared when studied during 
the treatment, and risperidone decreased burying behavior in 
the two groups. Although the burying/digging behavior that is 
evaluated during the SIT is not a behavior with respect to any 
object, the behavior is similar to that which is measured, in a more 
directed way, in the marble burying test.
Investigations with other mouse models such as male ICR 
treated with risperidone at a dose of 1 mg/kg, p.o. have observed 
that risperidone treatment is effective in reducing the number 
of buried marbles, although it also reduces locomotor activity 
(Matsushita et al., 2005). This effect is also shown in male BTBR 
mice (Gould et al., 2011) and in NIH Swiss male mice (Li et al., 
2006). Likewise, in male NMRI mice, risperidone, at a dose of 
0.16–0.63 mg/kg, significantly reduces marble behavior and 
locomotor activity, suggesting that the antagonist action of the 
drug 5-HT2A receptor may contribute to the effectiveness of the 
burying of marbles and having anxiolytic effect (Bruins Slot et al., 
2005). According to these results, it can be said that risperidone, 
at a low dose without cataleptic effect, can effectively reduce the 
number of buried marbles (Bardin et al., 2006).
Glucose levels. Antipsychotic drugs can cause a variety of 
metabolic problems such as weight gain, hyperglycemia, lipid 
abnormalities, and development of type 2 diabetes. Given these 
serious health risks, FDA requested that antipsychotics of second 
generation such as clozapine, olanzapine, risperidone, quetiapine, 
ziprasidone, and aripiprazole should be labeled to indicate that 
they increase the risk of developing diabetes (Cope et al., 2009 
and Savoy et al., 2010). In the case of increased vulnerability to 
higher mortality risk in AD induced by atypical antipsychotics, 
the metabolic syndrome has been hypothesized initially as one of 
the possible risk factors. Antipsychotics bind with high affinity 
to a wide variety of neurotransmitter and transporter receptors 
that could be involved in various metabolic effects; however, the 
underlying mechanisms are not entirely clear.
In the basal study, we evaluated baseline fasting glucose levels 
as well as ip glucose tolerance test (IPGTT) and we repeated the 
measurement of basal glucose levels, this time without fasting, 
after chronic treatment with risperidone. The glucose tolerance 
test was ignored because it also involves fasting in animals added 
to the normal fast in the light phase and the consequent loss of 
weight that, at these ages, could affect the survival curves of the 
animals.
As in the basal characterization phase, no genotype differences 
were observed during the treatment phase but genotype × 
treatment interaction effects. These effects resulted, however, 
from a significant decrease in glucose levels in the NTg (r) mice 
compared to those in the NTg (s) animals or when the glycemic 
values of the NTg (r) were compared longitudinally with those 
obtained before treatment. The results also agree with studies 
carried out in our laboratory with 3xTg-AD animals at 6 months 
of age in which we observed, in both sexes, that the basal levels 
of plasma glucose with and without fasting are normal, with the 
homeostasis of glucose being the one that is compromised in 
3xTg-AD mice, although with aging, the genotype differences 
are lost (Giménez-Llort et al., 2010). Studies in male C57BL/6 
mice administered with risperidone showed a slight increase in 
blood glucose levels, but only at a low dose of the drug (Dwyer 
and Donohoe, 2003), while other more recent studies, with 
males FVB/N mice, observed a significant reduction of plasma 
glucose (-30%) through the induction of insulin release (Savoy 
et al., 2010).
Body weight curves. The results on weight in patients with AD 
treated with antipsychotics are somewhat contradictory since there 
are studies that indicate that the administration of risperidone, 
olanzapine, or quetiapine at low doses is not associated with 
weight gain (Rondanelli et al., 2006). However, other research 
indicates that the use of olanzapine and quetiapine significantly 
increases weight in women and modifies cholesterol levels (Zheng 
et al., 2009). At the experimental level, weight measurements are 
a good indicator of the health status of the animal. In addition, in 
this study, we can evaluate the possible effect of chronic treatment 
with risperidone in this variable, in addition to the fact that weight 
is required to administer the correct dose of treatment.
For these reasons, it was decided to make a longitudinal 
follow-up of the weight from the beginning of the experimental 
process to the end of the mice’s life. According to our own data, 
higher BW was found in the 3xTg-AD mice (Giménez-Llort 
et al., 2007), and as they advanced in age, these differences were 
attenuated. Risperidone produced a weight loss only in 3xTg-AD 
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mice, while groups of NTg mice maintained their BW. In the final 
stages of the animal’s life, an acute weight loss was observed and 
this, immediately after the death, was found to be diminished in 
the four experimental groups, although the process of cachexia 
and the dehydration intrinsic to the death process make the data 
to lose accuracy. Previous studies with 6-month-old 3xTg-AD 
mice (males and females) have observed a decrease in the 
weight curve only in the group of females in potentially stressful 
situations (Giménez-Llort et al., 2010). This could be because 
they are more sensitive to repeated handling or the exposure 
of behavioral tests; however, it cannot be stated to what extent 
weight loss can be associated with emotional reactivity.
Several studies suggest that weight reduction may be 
associated with decreased activity but depending on the doses 
administered. Some authors have shown a relationship of the 
neuroleptic effects of olanzapine, ziprasidone, and risperidone 
with the decrease in food intake, the reduction of body mass, and 
motor activity since these changes are only present in wild-type 
mice but not in D2R knockout mice (Yoon et al., 2010). However, 
treatment with risperidone 4 mg/kg p.o. in female C57BL/6J mice 
of 12 weeks of age induces an increase in food consumption, the 
corresponding weight gain, an increase in body temperature 
during the light phase, and a reduction in the activity during the 
dark phase (Cope et al., 2009).
Life expectancy and survival. Treatment with atypical 
antipsychotics may double the risk of mortality in elderly patients 
with dementia, although this risk is similar to or even lower than 
antipsychotics. The increase in risk is faster in antipsychotic 
treatment and does not seem to be related either to the dose or to 
the type of substance (Vilalta-Franch et al., 2008). Recent studies 
have indicated that patients with dementia and prescription 
antipsychotics such as thioridazine, chlorpromazine, haloperidol, 
trifluoperazine, and risperidone to treat neuropsychiatric 
symptoms increased the long term risk. The most pronounced 
difference will be between 24 and 36 months after the start of 
treatment (Ballard et al., 2009; Kales et al., 2012). In addition, 
on other mental pathologies such as bipolar disorder in the 
elderly patient, risperidone has a higher incidence of mortality 
associated as compared to quetiapine (Bhalerao et al., 2012).
Our longitudinal study replicates the increased mortality 
described in male 3xTg-AD mice as compared to age-matched 
NTg mice by our laboratory (Giménez-Llort et al., 2008) and 
demonstrates that this animal can model the vulnerability to 
increased mortality risk associated with risperidone in the human 
patients. Thus, the group of NTg (s) mice maintained their survival 
intact until 19 months of age, while the start of mortality was 
during 15 months of age for the groups of NTg (r), 3xTg-AD (s), 
and 3xTg-AD (r). In previous studies with 15-month-old males 
3xTg-AD and NTg mice, the increase in mortality, evaluated from 
6 to 15 months of age, was 40%. In the present study, at the same 
age, the percentage was 15% since survival was recorded from 12 
months and, therefore, mortalities that occurred earlier (i.e., from 
6 months of age) were not counted (Giménez-Llort et al., 2008). 
Increased mortality in 10–20-month-old male 3xTg-AD mice 
as compared to B6129F2 wild-type controls has also been found 
by other laboratories and shown to be accompanied by elevated 
frailty scores (Kane et al., 2018).
The total life expectancy, the mean life expectancy, and the 
life expectancy with a lifespan of 25% showed the predominant 
effects of the genotype, but also the effect of risperidone in the 
range of ages below. Therefore, although the survival curves in the 
mice treated with risperidone and saline showed similar slopes in 
the four experimental groups, the initial vulnerability and from 
the mean life expectancy determined important changes in the 
maximum survival recorded. In NTg mice, this maximum was 
reduced by 8 months with the risperidone treatment (from 36 
to 28 months), and in groups of 3xTg-AD mice, the maximum 
survival was reduced by 2 months (from 24 to 22 months). The data 
suggest, in addition, that risperidone exerted deleterious effects in 
NTg animals that equaled them in vulnerability to animals with 
3xTg-AD genotype. This deleterious effect of risperidone in NTg 
animals was mainly observable between 15 and 17 months of age, 
although it reappeared in the age ranges corresponding to their 
half-life expectancy (24 and 25 months, respectively) and the 
difference persisted until the end of the curve.
The behavioral correlates for survival pointed out variables 
and tests related to the BPSD-like phenotype, in agreement with 
the neuroimmunoendocrine hypothesis (Giménez-Llort et al., 
2014) pointing at sex-specific neuroimmunoendocrine aging in 
3xTg-AD mice and its relation with longevity (Giménez-Llort 
et  al., 2008). The crosstalk refers to the oxi-inflamaging theory 
developed in PAM and NPAM mice where the divergence of 
the speed of the aging process (premature in PAM and normal 
in NPAM) was correlated with immune function, oxidative 
stress, and worse/better copying with stress strategies in the TM 
(Guayerbas et al., 2001). While neophobia and worse long-term 
memory were found to be correlated with reduced survival in 
female NTg and 3xTg-AD mice (Torres-Lista et al., 2017), it was 
surprising that memory variables did not correlate with survival in 
the present work, probably due to the mortality bias, as discussed 
above. Thus, this was probably because the impairment was less 
pronounced in the current male sample, as correlation was only 
found with the level of optimization of the performance (day 4) 
in the water maze. Interestingly, the effects of risperidone on 
social behaviors in the NTg mice were the ones to correlate with 
survival, with faster body/face interaction and delayed elicitation 
of vibrating tail being correlated with longer longevity of NTg 
(r) animals, but also when the whole sample of animals was 
considered. This is important to note, since, to our knowledge, 
it is the first time that social behavior is being related to lifespan.
Risperidone is mainly metabolized in the liver (Mannens et al., 
1993 and Zhou et al., 2006) by the enzyme cytochrome P-450 
2D6 (CYP2D6), which has more than 20 genetic polymorphisms 
(Leysen et al., 1988; Mannens et al., 1993 and Matsubara et al., 
2007). Whether biological aspects related to the individual 
variability in drug metabolism either by polymorphisms or 
by hepatomegaly (Marchese et al., 2014) explain the increased 
mortality risk remains to be elucidated.
In summary, in this longitudinal study, the effects of the 
chronic administration of risperidone on cognition and 
BPSD-like (motor, NPS, emotional, and social) symptoms 
were evaluated in male 3xTg-AD and NTg mice, as well as the 
short- and long-term impact on their survival. It was observed 
that the factors “genotype,” “treatment,” and “genotype × 
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treatment” interaction effects were present in most of the 
behaviors studied, such as decreased neophobia, and improved 
the development of exploratory activity in the open field in NTg 
mice but had a weak effect on these variables in the 3xTg-AD 
mice model. Risperidone was effective in reducing the 
number of marbles buried in the groups of mice that received 
antipsychotics with respect to the groups that were given 
saline. The study replicated, in 3xTg-AD mice, the increased 
mortality risk associated to risperidone observed at a clinical 
level in humans. Thus, despite the fact that risperidone allowed 
to modify the alterations shown by the 3xTg-AD mice in their 
interaction with congeners (social behavior) or environment 
(burying behavior of marbles), it exerted negative effects 
by reducing the vertical and horizontal exploratory activity 
in the tests. What is more relevant, chronic treatment with 
risperidone severely compromised the life expectancy of the 
animals already since the beginning of treatment as shown by 
early mortality windows. The impact of this mortality on the 
analysis of “before–after treatment” effects on the censured 
data is relevant to note since it further suggests that the 
reported effects are those exerted in the “less worse” animals, 
that is, those that are able to survive during the period of 
behavioral assessment. In the same way, risperidone exerted 
especially severe effects in the old NTg animals, also modeling, 
at the experimental level, the window of early vulnerability 
described for the adverse effects of cerebrovascular risk in 
the elderly treated with atypical antipsychotics. The results 
support the awareness on the use of risperidone and the 
associated increased risk of mortality in AD, which suggests 
the relevance of the dosage (dose and treatment period) and 
that this treatment has to be used in short-term schedules to 
address the symptoms that cause morbidity and pain in the 
patient and to diminish the potential of self-hurt. The decision 
to use atypical antipsychotics should be based on the patient’s 
medical history and both the benefit and the risk of treatment. 
At the translational level, the 3xTg-AD mice model and their 
NTg counterparts can be useful to delimitate critical time 
windows and for studying the physio-pathogenic factors and 
underlying causal events involved in this topic of considerable 
public health significance.
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